v3.26.3
Revenues (Tables)
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Product and Geographic Area The following table represents total net revenues by product line:
HIV
Sample Management Solutions (1)
HCV
Other products and services revenues (2)
COVID-19 (3)
Risk Assessment Testing (4)
Net product and services revenues
Non-product and services revenues (5)
Net revenues
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2026202520262025
$12,116 $11,141 $39,305 $38,439 
12,498 10,306 31,431 29,271 
3,221 2,604 9,277 11,063 
2,235 1,196 6,138 2,963 
22 89 41 578 
— — — 1,866 
30,092 25,336 86,192 84,180 
815 1,749 3,279 4,078 
$30,907 $27,085 $89,471 $88,258 
(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2) Includes Syphilis, Ebola, and Sickle SCAN® product revenues and single order fulfillment.
(3) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(4) Includes substance abuse testing product revenues.
(5) Includes funded research and development contracts, royalty income and grant revenues.
The following table represents total net revenues by geographic area, based on the location of the customer:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2026202520262025
United States$20,532 $19,662 $59,439 $60,070 
Africa6,399 4,875 19,959 19,023 
Europe2,223 1,300 5,415 5,064 
Other regions1,753 1,248 4,658 4,101 
$30,907 $27,085 $89,471 $88,258 
Schedules of Concentration of Risk, by Risk Factor The following table represents customer concentration risk:
For the Three Months Ended September 30,
Net Revenues20262025
Commercial customer(1)
10 %N/A
September 30,December 31,
Accounts Receivable20262025
Commercial customer (1)
20 %15 %
Commercial customer (1)
11 %N/A
(1) Each commercial customer is a different international distributor.
Schedule of Deferred Revenue
The following table represents deferred revenue recognized:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
Deferred Revenue Recognized2026202520262025
Accrued at beginning of year$39 $529 $1,148 $1,991